Xencor | XNCR - Sales Revenues


Xencor reported $21M in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alnylam Pharmaceuticals USD 1.25B 476.31M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
AstraZeneca USD 15.19B 733M Sep/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Cytokinetics USD 1.93M 64.83M Sep/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
J&J USD 24.6B 610M Dec/2025
MacroGenics USD 72.84M 50.6M Sep/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Xencor USD 21M 22.61M Sep/2025